Areal-world test of camrelizumab plus apatinib for liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and can be male or female
- You have confirmed hepatocellular carcinoma, with at least one measurable spot on scans
- Your cancer cannot be removed by surgery and has not responded well to prior systemic (whole-body) treatment
- Your liver function is still okay (Child-Pugh grade A or B) and your energy level is good (ECOG 0–1)
- You are able to follow the study plan for at least 12 weeks (and agree to join)
- If you have hepatitis B, it must be controlled (HBV viral load ≤ 2000, or treated with antivirals first if higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests whether combining two drugs, camrelizumab (an immunotherapy) and apatinib (a targeted therapy), can prevent liver cancer from coming back in people who've had surgery or ablation to remove their tumor. It's for patients with a high risk of recurrence.
This Phase 3 trial tests whether combining camrelizumab and apatinib with TACE before/around liver cancer surgery can improve outcomes for people with certain stages of hepatocellular carcinoma (HCC). It may help by strengthening the immune attack on cancer and by blocking blood supply to tumors.
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.